Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide

被引:19
作者
Blomquist, DV
Green, P
Laidlaw, SM
Skinner, MA
Borrow, P [1 ]
Duarte, CA
机构
[1] Edward Jenner Inst Vaccine Res, Newbury RG20 7NN, Berks, England
[2] Ctr Ingn Genet & Biotecnol, Havana, Cuba
[3] AFRC, Inst Anim Hlth, Newbury RG16 0NN, Berks, England
关键词
D O I
10.1089/08828240260066260
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recombinant avipoxvirus vectors are attractive candidates for use in vaccination strategies for infections such as human immunodeficiency virus type 1 (HIV-1), where induction of a CD8(+) T cell response is thought to be an important component of protective immunity. Here, we report the expression of a multiepitope polypeptide (TAB9) composed of the central 15 amino acids of the V3 loop from six different isolates of HIV-1 in a fowlpox virus (FWPV) vector, and the use of this vector (FPTAB9LZ) to induce strong HIV-specific CD8(+) T cell responses in mice. In animals immunized twice intravenously with FPTAB9LZ, almost 2% of the CD8(+) T cells in the spleen were shown to produce IFN-gamma in response to stimulation with HIV-1 peptides 1 week after the second immunization. The most dominant response was to the HIV-1 IIIB peptide. A strong HIV-specific response was also induced by intraperitoneal immunization of mice with FPTAB9LZ, whilst subcutaneous immunization elicited a weaker response. Intraperitoneal immunization with FPTAB9LZ was also shown to provide protection against challenge with a recombinant vaccinia virus expressing antigens, including those in TAB9. These results confirm the potential of FWPV vectors for use in HIV vaccination strategies.
引用
收藏
页码:337 / 356
页数:20
相关论文
共 87 条
[1]   A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) [J].
Adler, SP ;
Plotkin, SA ;
Gonczol, E ;
Cadoz, M ;
Meric, C ;
Ben Wang, JA ;
Dellamonica, P ;
Best, AM ;
Zahradnik, J ;
Pincus, S ;
Berencsi, K ;
Cox, WI ;
Gyulai, Z .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :843-846
[2]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[3]   Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen [J].
Allen, TM ;
Vogel, TU ;
Fuller, DH ;
Mothé, BR ;
Steffen, S ;
Boyson, JE ;
Shipley, T ;
Fuller, J ;
Hanke, T ;
Sette, A ;
Altman, JD ;
Moss, B ;
McMichael, AJ ;
Watkins, DI .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4968-4978
[4]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[5]  
An LL, 1999, CURR OPIN MOL THER, V1, P16
[6]   Vaccination with HIV 1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit [J].
Barnett, SW ;
Rajasekar, S ;
Legg, H ;
Doe, B ;
Fuller, DH ;
Haynes, JR ;
Walker, CM ;
Steimer, KS .
VACCINE, 1997, 15 (08) :869-873
[7]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[8]   Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination [J].
Barouch, DH ;
Santra, S ;
Kuroda, MJ ;
Schmitz, JE ;
Plishka, R ;
Buckler-White, A ;
Gaitan, AE ;
Zin, R ;
Nam, JH ;
Wyatt, LS ;
Lifton, MA ;
Nickerson, CE ;
Moss, B ;
Montefiori, DC ;
Hirsch, VM ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2001, 75 (11) :5151-5158
[9]   Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers [J].
Belshe, RB ;
Stevens, C ;
Gorse, GJ ;
Buchbinder, S ;
Weinhold, K ;
Sheppard, H ;
Stablein, D ;
Self, S ;
McNamara, J ;
Frey, S ;
Flores, J ;
Excler, JL ;
Klein, M ;
El Habib, R ;
Duliege, AM ;
Harro, C ;
Corey, L ;
Keefer, M ;
Mulligan, M ;
Wright, P ;
Celum, C ;
Judson, F ;
Mayer, K ;
McKirnan, D ;
Marmor, M ;
Woody, G .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (09) :1343-1352
[10]   Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251:: Dependence on route of challenge exposure [J].
Benson, J ;
Chougnet, C ;
Robert-Guroff, M ;
Montefiori, D ;
Markham, P ;
Shearer, G ;
Gallo, RC ;
Cranage, M ;
Paoletti, E ;
Limbach, K ;
Venzon, D ;
Tartaglia, J ;
Franchini, G .
JOURNAL OF VIROLOGY, 1998, 72 (05) :4170-4182